Vertex Pharmaceuticals Incorporated (VRTX)
Vertex (VRTX) NDA for Vanza Triple Therapy Accepted by FDA
The FDA accepts Vertex's (VRTX) new drug application for vanza triple therapy for people living with cystic fibrosis aged six years and above. A decision is due on Jan 2, 2025.
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $474.95, signifying a +1.33% move from its prior day's close.
Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Forget Eli Lilly, Buy This Magnificent Biotech Stock Instead
This magnificent drugmaker is much smaller than Eli Lilly, but is still large and successful. It has massive growth opportunities in multiple markets.
Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $467.28, indicating a -1.35% shift from the previous trading day.
Vertex Pharmaceuticals (VRTX) Stock Declines While Market Improves: Some Information for Investors
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $475.79, signifying a -1.19% move from its prior day's close.
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Vertex Pharmaceuticals Incorporated (VRTX) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024 11:20 AM ET Company Participants David Altshuler - Chief Scientific Officer Charles Wagner - CFO Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Great. Good morning, everyone.
Vertex Pharmaceuticals Incorporated (VRTX) The 44th Annual William Blair Growth Stock Conference
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) The 44th Annual William Blair Growth Stock Conference June 4, 2024 5:00 PM ET Company Participants Reshma Kewalramani - Chief Executive Officer Conference Call Participants Myles Minter - William Blair Sami Corwin - William Blair Myles Minter All right, thank you very much. Welcome back to the William Blair Growth Stock Conference, the 44th Edition, as I understand it.
Why Is Vertex (VRTX) Up 15.8% Since Last Earnings Report?
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?
Why Vertex Pharmaceuticals (VRTX) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
